Side population cells originated from human amnion and their uses
First Claim
Patent Images
1. A side population cell separated from human amniotic mesenchymal cell layer, in which expressions of Oct-4 gene, Sox-2 gene and Rex-I gene are observed by RT-PCR, and which is vimentin-positive and CK19-positive in immunocytostaining.
1 Assignment
0 Petitions
Accused Products
Abstract
Cells which may be differentiated at least into nerve cells, which are useful for therapies of brain metabolic diseases, are disclosed. The cells are side population cell separated from human amniotic mesenchymal cell layer, in which expressions of Oct-4 gene, Sox-2 gene and Rex-1 gene are observed by RT-PCR, and which are vimentin-positive and CK19-positive in immunocytostaining.
-
Citations
7 Claims
- 1. A side population cell separated from human amniotic mesenchymal cell layer, in which expressions of Oct-4 gene, Sox-2 gene and Rex-I gene are observed by RT-PCR, and which is vimentin-positive and CK19-positive in immunocytostaining.
-
3. An assemblage of side population cells separated from human amniotic mesenchymal cell layer, comprising cells which are major histocompatibility antigen class II-negative and major histocompatibility antigen class I-negative, and cells which are major histocompatibility antigen class II-negative and major histocompatibility antigen class I-positive.
- 4. A method for transplantation comprising transplanting side population cells separated from human amniotic mesenchymal cell layer.
-
6. A method for therapy of a brain metabolic disease, comprising administering an effective amount of side population cells separated from human amniotic mesenchymal cell layer.
-
7. A method for therapy of β
- -galactosidase-deficiency and/or β
-glucosidase-deficiency, comprising administering an effective amount of side population cells separated from human amniotic mesenchymal cell layer.
- -galactosidase-deficiency and/or β
Specification